Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Rating of "Moderate Buy" from Analysts

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven brokerages that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $27.94.

A number of research firms have issued reports on KURA. HC Wainwright restated a "buy" rating and set a $32.00 price target on shares of Kura Oncology in a report on Tuesday, May 14th. StockNews.com cut shares of Kura Oncology from a "hold" rating to a "sell" rating in a research note on Monday, April 15th. JMP Securities reissued a "market outperform" rating and set a $32.00 price target on shares of Kura Oncology in a research note on Thursday. Finally, Wedbush reaffirmed an "outperform" rating and issued a $37.00 price objective on shares of Kura Oncology in a research note on Friday, May 3rd.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Artal Group S.A. boosted its position in Kura Oncology by 8.6% during the first quarter. Artal Group S.A. now owns 1,919,884 shares of the company's stock worth $40,951,000 after purchasing an additional 151,828 shares during the period. Price T Rowe Associates Inc. MD boosted its position in Kura Oncology by 17.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 20,148 shares of the company's stock worth $430,000 after purchasing an additional 2,940 shares during the period. Avoro Capital Advisors LLC boosted its position in Kura Oncology by 29.2% during the first quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company's stock worth $82,120,000 after purchasing an additional 870,000 shares during the period. Affinity Asset Advisors LLC boosted its position in Kura Oncology by 281.4% during the first quarter. Affinity Asset Advisors LLC now owns 730,492 shares of the company's stock worth $15,581,000 after purchasing an additional 538,957 shares during the period. Finally, Platinum Investment Management Ltd. bought a new position in Kura Oncology during the first quarter worth about $998,000.

Kura Oncology Price Performance

KURA traded down $0.81 during trading on Friday, reaching $22.17. The stock had a trading volume of 582,334 shares, compared to its average volume of 781,101. The firm has a market capitalization of $1.69 billion, a price-to-earnings ratio of -10.22 and a beta of 0.89. Kura Oncology has a 1-year low of $7.41 and a 1-year high of $24.17. The stock has a 50 day moving average of $20.56 and a two-hundred day moving average of $16.97. The company has a quick ratio of 16.67, a current ratio of 16.67 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its earnings results on Thursday, May 2nd. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.03). Kura Oncology's revenue for the quarter was up .0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.50) EPS. As a group, equities analysts anticipate that Kura Oncology will post -2.56 EPS for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.